Development of small near infrared laser system capable of improving immune responses to vaccines laser based adjuvant

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R42AI114012-02
Agency Tracking Number: R42AI114012
Amount: $1,387,772.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA14-072
Timeline
Solicitation Year: 2014
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-08-05
Award End Date (Contract End Date): 2018-07-31
Small Business Information
15 VICTORIA DR., Epping, NH, 03042-2536
DUNS: 079757419
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 DAVID BEAN
 (978) 273-3562
 dbean@veralase.com
Business Contact
 DAVID BEAN
Phone: (978) 273-3562
Email: dbean@veralase.com
Research Institution
 MASSACHUSETTS GENERAL HOSPITAL
 55 FRUIT STREET
BOSTON, MA, 02114-2696
 Domestic nonprofit research organization
Abstract
DESCRIPTION provided by applicant The lack of vaccine adjuvants that are both safe and effective is an important public health problem and is a key research priority for the NIH NIAID No adjuvants have yet been approved for use with intradermal vaccines The goal of this phase II STTR project is to move a new adjuvant for intradermal vaccination small near infrared lasers that emit brief non damaging non painful light doses to a small area of skin to the point of advanced preclinical development In the phase I project our team successfully showed that small diode laser systems could augment immune responses to a vaccine in an established mouse model The phase II project has three specific aims Design and construct a small near infrared diode laser device appropriate for clinical use with intradermal vaccines Show in an animal model that such a device can enhance an intradermal chikungunya virus vaccine enabling a significant decrease in antigen dose dose number or both Show that that laser exposures are tolerable and non damaging in humans while stimulating skin immune signaling and immune cell mobilization Laser based adjuvanting approaches have not been moved beyond academic studies this phase II project will help move a laser based adjuvant toward the clinic at which point it could be licensed as an adjuvant for multiple vaccines The broad and long term objectives of this project are to improve vaccines by increasing the range of new adjuvants available for use with vaccine antigens and to expand the application of intradermal vaccines that can offer protection from diseases through safer less painful and more efficient vaccination approaches Laser design will start with assessment of how the adjuvant would be used in clinical vaccination and will move to iterative prototype development that incorporates these design considerations and leverages our existing laser manufacturing resources The final prototype will be bench tested to validate consistent achievement of design requirements and a scalable quality based manufacturing process will be established In parallel three different near infrared lasers will be tested in a mouse vaccine model to determine the specific configuration that best enhances an intradermal vaccine against chikungunya virus These studies will be conducted by Dr Satoshi Kashiwagi at the Vaccine and Immunotherapy Center Massachusetts General Hospital and Dr Ted Ross at the College of Veterinary Medicine University of Georgia They will demonstrate the ability of the laser adjuvant to provide equivalent protection to a non adjuvanted vaccine at reduced dose size or number Finally the laser that works best in these mouse studies will be tested in humans to show that it does not hurt or cause any skin damage and produces similar immune stimulating effects in the skin that are seen in mice This laser will be tested in human subjects of all skin tones to show that skin responses to the laser are not affected by pigmentation This clinical study will be conducted by Northeast Dermatology Associates PA Together these three aims will prepare the laser adjuvant for continued development in preparation for clinical trials PUBLIC HEALTH RELEVANCE Many vaccines use additional chemical compounds called adjuvants to make them work better but these adjuvants can cause discomfort at the place the vaccine is given or result in other unwanted health effects Based on our findings that a new kind of adjuvant that consists of laser light rather than chemicals can increase vaccine efficacy we have developed a laser device that is able to deliver such laser light to make vaccines work better This proposal aims to continue to develop a laser device for vaccines that could be used in the clinic with an ultimate goal to make vaccines work better while being safer and making vaccination less painful

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government